ES2164011B1 - COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS. - Google Patents
COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.Info
- Publication number
- ES2164011B1 ES2164011B1 ES200000459A ES200000459A ES2164011B1 ES 2164011 B1 ES2164011 B1 ES 2164011B1 ES 200000459 A ES200000459 A ES 200000459A ES 200000459 A ES200000459 A ES 200000459A ES 2164011 B1 ES2164011 B1 ES 2164011B1
- Authority
- ES
- Spain
- Prior art keywords
- substances
- treatment
- combined use
- tumors
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000126 substance Substances 0.000 abstract 6
- 102000013462 Interleukin-12 Human genes 0.000 abstract 3
- 108010065805 Interleukin-12 Proteins 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 229940117681 interleukin-12 Drugs 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000006023 anti-tumor response Effects 0.000 abstract 1
- 201000010897 colon adenocarcinoma Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso combinado de la quimiocina IP-10 y la interleucina-12 en la preparación de composiciones para el tratamiento de tumores malignos. La invención se relaciona con el uso combinado de la quimiocina IP-10 y la interleucina-12 como terapia frente a tumores malignos, así como el uso de IP-10 para potenciar el efecto antitumoral de IL-12. Estas dos sustancias son proteínas inmunomoduladoras que potencian la respuesta antitumoral. La administración en mamíferos de ambas sustancias en combinación permite aumentar la actividad anti-tumoral en el mamífero portador del tumor. La administración de ambas sustancias puede realizarse mediante proteína recombinante preparada in-vitro o mediante sistemas de expresión o transferencia génica que expresen dichas sustancias. La combinación de ambas substancias tiene un efecto sinérgico en la inducción de linfocitos citotóxicos específica frente a tumores. La combinación de ambas sustancias, en las proporciones y dosis adecuadas para cada caso, puede ser útilpara el tratamiento de cualquier tipo de cáncer como por ejemplo el adenocarcinoma de colon.Combined use of chemokine IP-10 and interleukin-12 in the preparation of compositions for the treatment of malignant tumors. The invention relates to the combined use of chemokine IP-10 and interleukin-12 as a therapy against malignant tumors, as well as the use of IP-10 to enhance the antitumor effect of IL-12. These two substances are immunomodulatory proteins that enhance the antitumor response. The administration in mammals of both substances in combination allows to increase the anti-tumor activity in the tumor-bearing mammal. The administration of both substances can be carried out by recombinant protein prepared in-vitro or by gene expression or transfer systems expressing said substances. The combination of both substances has a synergistic effect on the induction of specific cytotoxic lymphocytes against tumors. The combination of both substances, in the appropriate proportions and doses for each case, can be useful for the treatment of any type of cancer such as colon adenocarcinoma.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200000459A ES2164011B1 (en) | 2000-02-25 | 2000-02-25 | COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS. |
| PCT/ES2001/000066 WO2001062274A1 (en) | 2000-02-25 | 2001-02-22 | Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors |
| AU2001233811A AU2001233811A1 (en) | 2000-02-25 | 2001-02-22 | Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200000459A ES2164011B1 (en) | 2000-02-25 | 2000-02-25 | COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2164011A1 ES2164011A1 (en) | 2002-02-01 |
| ES2164011B1 true ES2164011B1 (en) | 2003-05-16 |
Family
ID=8492479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200000459A Expired - Lifetime ES2164011B1 (en) | 2000-02-25 | 2000-02-25 | COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS. |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001233811A1 (en) |
| ES (1) | ES2164011B1 (en) |
| WO (1) | WO2001062274A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041302B2 (en) | 2001-01-09 | 2006-05-09 | Biother Corporation | Therapeutic modulation of the tumor inflammatory response |
| AU2004204719A1 (en) * | 2003-01-07 | 2004-07-29 | Children's Hospital Medical Center | Cytokine inhibition of eosinophils |
| JP6912384B2 (en) | 2015-04-22 | 2021-08-04 | キュアバック アーゲー | RNA-containing compositions for the treatment of cancer diseases |
| DK3458083T5 (en) | 2016-05-18 | 2024-10-21 | Modernatx Inc | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF |
| CN110337305A (en) | 2017-02-28 | 2019-10-15 | 赛诺菲 | Therapeutic RNA |
| CA3063723A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
| WO2019075452A1 (en) * | 2017-10-13 | 2019-04-18 | Evelo Biosciences, Inc. | Identification of bacteria for cancer therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1100941A2 (en) * | 1998-07-27 | 2001-05-23 | Valentis Inc. | Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same |
-
2000
- 2000-02-25 ES ES200000459A patent/ES2164011B1/en not_active Expired - Lifetime
-
2001
- 2001-02-22 WO PCT/ES2001/000066 patent/WO2001062274A1/en not_active Ceased
- 2001-02-22 AU AU2001233811A patent/AU2001233811A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001233811A1 (en) | 2001-09-03 |
| ES2164011A1 (en) | 2002-02-01 |
| WO2001062274A1 (en) | 2001-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hughes et al. | T‐cell modulation by cyclophosphamide for tumour therapy | |
| Sersa et al. | Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompotent and immunodeficient mice | |
| Whelan et al. | The role of interferons in the treatment of osteosarcoma | |
| Moschella et al. | Combination strategies for enhancing the efficacy of immunotherapy in cancer patients | |
| Kelly et al. | Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. | |
| Vasekar et al. | Immunotherapy in bladder cancer | |
| BR9407956A (en) | Pharmaceutical composition vector of recombinant adenovirus expression and kit to reduce tumor cell proliferation | |
| DK1401458T3 (en) | Composition consisting of PHY906 and chemotherapeutic agents | |
| BR0113491A (en) | Isolated polynucleotide and polypeptide, expression vector, host cell, fusion protein, methods for stimulating and / or expanding tumor protein-specific T cells to stimulate an immune response in a patient, to treat cancer in a patient and to inhibit cancer development in a patient, isolated t-cell population, composition, and use of a component. | |
| NZ226005A (en) | Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof | |
| EA201200560A1 (en) | SPECIFIC THERAPY USING INTEGRINE LIGANDS FOR CANCER TREATMENT | |
| ES2134294T3 (en) | IMMUNE REACTIVITY FOR EXPRESSIVE ACTIVE ONCOGENS FOR DIAGNOSIS AND TREATMENT OF MALIGNANT TUMORS. | |
| Wang et al. | Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer | |
| WO2004096159A3 (en) | Saposin c-dops: a novel anti-tumor agent | |
| WO2020018996A3 (en) | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment | |
| ES2164011B1 (en) | COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS. | |
| Teicher et al. | In vivo studies with Interleukin‐12 alone and in combination with monocyte colony‐stimulating factor and/or fractionated radiation treatment | |
| DK1325739T3 (en) | Liposomes encapsulating anti-cancer drugs and their use in the treatment of malignant tumors | |
| Teicher et al. | Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. | |
| Hiramatsu et al. | CpG oligodeoxynucleotides potentiate the antitumor activity of anti‐BST 2 antibody | |
| ES2039236T3 (en) | METHOD FOR PREPARING A THERAPEUTIC COMPOSITION OF INTERLENQUINE-2 AND / OR INTERFERON-BETA AND TUMOR NECROSIS FACTOR. | |
| DK1161250T3 (en) | Immunostimulatory bacterial membrane fractions in cancer treatment | |
| van Herpen et al. | Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma | |
| EP1812035A4 (en) | PEPTIDE ANTITUMOR AGENT | |
| Bernsen et al. | Interleukin-2: hope in cases of cisplatin-resistant tumours |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20020201 Kind code of ref document: A1 Effective date: 20020201 |
|
| FG2A | Definitive protection |
Ref document number: 2164011B1 Country of ref document: ES |
|
| FA2A | Application withdrawn |
Effective date: 20031120 |